



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Lupin Appoints Martin Mercer as President of its Latin American Business

Mumbai, Baltimore, October 26, 2015: Pharma major Lupin Limited today announced the appointment of Martin Mercer as its President for Latin America. He will be based at Naples, Florida. Martin joins Lupin from Astellas Pharma where he was the Head of Latin America. Prior to that, he has worked at Valeant as Head of Latin America & International business as well as Glaxo in Regional Management positions. He started his career in Glaxo and worked his way through multiple roles of increasing responsibility in various Latin American markets. Other than successfully building and scaling large businesses in diverse geographies of Latin America, Martin has significant experience in acquisition integration, change management & restructuring, business development and new product development.

In his new role at Lupin, Martin will assume full responsibility for the Company's Latin American business including the company's overall strategy for its generics & specialty business in Brazil, Mexico, Venezuela, Colombia and Argentina.

Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin Limited said, "We're delighted to welcome Martin into the Lupin family. We believe that Martin's rich experience in Latin America will be an asset when it comes to expanding and strengthening Lupin's businesses in the region. The Latin American region is a market of strategic focus for the company and one of the fastest growing pharmaceutical markets globally."

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 6th largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 8th) and South Africa (ranked 4th – IMS Health). For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion) and Rs. 24,032 million (USD 393 million) respectively.

Please visit <http://www.lupin.com> for more information.

You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098

For further information or queries please contact -

Press Release



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited
Ph: +91 98 20 338 555
Email: shamshergorawara@lupin.com

or

Alpesh Dalal
Head – M & A and Investor Relations
Lupin Limited
Ph: +91 98 20 023 511
Email: alpeshdalal@lupin.com

[Safe Harbor Statement](#)